 |
|
Evolution of Tuberculosis Control and Prospects for Reducing Tuberculosis Incidence, Prevalence, and Deaths Globally
Christopher Dye, DPhil;
Catherine J. Watt, DPhil;
Daniel M. Bleed, MD;
S. Mehran Hosseini, MD;
Mario C. Raviglione, MD
JAMA. 2005;293:2767-2775.
Context The United Nations Millennium Development Goals (MDGs) are stimulating more rigorous evaluations of the impact of DOTS (the WHO-recommended approach to tuberculosis control based on 5 essential elements) and other possible strategies for tuberculosis (TB) control.
Objective To evaluate the prospects for detecting 70% of new sputum smear–positive cases and successfully treating 85% of these by the end of 2005, for reducing TB incidence, and for halving TB prevalence and deaths globally between 1990 and 2015, as specified by the MDGs.
Data Sources TB case notifications (1980-2003) from DOTS and non-DOTS programs and cohort treatment outcomes (1994-2002) reported annually to the World Health Organization (WHO) by up to 200 countries, TB death registrations, and prevalence surveys of infection and disease.
Study Selection Case notification series that reflect trends in incidence, treatment outcomes from DOTS cohorts, death statistics from countries with WHO-validated vital registration systems, and national prevalence surveys of infection and disease.
Data Extraction Case reports, treatment outcomes, prevalence surveys, and death registrations from WHO's global TB database covering 1990-2003 to estimate TB incidence, prevalence, and death rates through 2015 for 9 epidemiologically different world regions.
Data Synthesis TB incidence increased globally in 2003, but incidence, prevalence, and death rates were approximately stable or decreased in 7 of 9 regions. The exceptions were regions of Africa with low (<4% in adults 15-49 years) and high rates ( 4%) of HIV infection. The global detection rate of new smear-positive cases by DOTS programs increased from 11% in 1995 to 45% in 2003 (with the lowest case-detection rates in Eastern Europe and the highest rates in the Western Pacific) and could reach 60% by 2005. More than 17 million patients were treated in DOTS programs between 1994 and 2003, with overall treatment success rates more than 80% since 1998. In 2003, overall reported treatment success was 82%, with much variation among regions. The highest rates were reported in the Western Pacific region (89%) and lowest rates in African countries with high and low HIV infection rates (71% and 74%, respectively), in established market economies (77%), and in Eastern Europe (75%). To halve the prevalence rate by 2015, TB control programs must reach global targets for detection (70%) and treatment success (85%) and also reduce the incidence rate by at least 2% annually. To halve the death rate, incidence must decrease more steeply, by at least 5% to 6% annually.
Conclusion Reduction of TB incidence, prevalence, and deaths by 2015 could be achieved in most of the world, but the challenge will be greatest in Africa and Eastern Europe.
Author Affiliations: Stop TB Department, World Health Organization, Geneva, Switzerland.
RELATED ARTICLES
Group Targets Surging TB in Africa
Mike Mitka
JAMA. 2005;293(22):2707.
EXTRACT
| FULL TEXT
Tuberculosis, Vulnerability, and Access to Quality Care
Philip C. Hopewell and Madhukar Pai
JAMA. 2005;293(22):2790-2793.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Demographic, health services and socio-economic factors associated with pulmonary tuberculosis mortality in Los Altos Region of Chiapas, Mexico
Najera-Ortiz et al.
Int J Epidemiol 2008;37:786-795.
ABSTRACT
| FULL TEXT
Long term efficacy of DOTS regimens for tuberculosis: systematic review
Cox et al.
BMJ 2008;336:484-487.
ABSTRACT
| FULL TEXT
Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls
Wejse et al.
Am. J. Clin. Nutr. 2007;86:1376-1383.
ABSTRACT
| FULL TEXT
Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice
de Steenwinkel et al.
J Antimicrob Chemother 2007;60:1064-1073.
ABSTRACT
| FULL TEXT
Quantitative Impact of Human Immunodeficiency Virus Infection on Tuberculosis Dynamics
DeRiemer et al.
Am. J. Respir. Crit. Care Med. 2007;176:936-944.
ABSTRACT
| FULL TEXT
Tuberculosis in London: the importance of homelessness, problem drug use and prison
Story et al.
Thorax 2007;62:667-671.
ABSTRACT
| FULL TEXT
Operational Feasibility of Using Loop-Mediated Isothermal Amplification for Diagnosis of Pulmonary Tuberculosis in Microscopy Centers of Developing Countries
Boehme et al.
J. Clin. Microbiol. 2007;45:1936-1940.
ABSTRACT
| FULL TEXT
Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth
Long et al.
J Antimicrob Chemother 2007;59:118-121.
ABSTRACT
| FULL TEXT
Diagnostic Yield of Sputum, Induced Sputum, and Bronchoscopy after Radiologic Tuberculosis Screening
Schoch et al.
Am. J. Respir. Crit. Care Med. 2007;175:80-86.
ABSTRACT
| FULL TEXT
Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents
Teo et al.
Antimicrob. Agents Chemother. 2006;50:3665-3673.
ABSTRACT
| FULL TEXT
The impact of physician training and experience on the survival of patients with active tuberculosis.
Khan et al.
CMAJ 2006;175:749-753.
ABSTRACT
| FULL TEXT
Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis.
Atun et al.
Health Policy Plan 2006;21:353-364.
ABSTRACT
| FULL TEXT
Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy
Warner and Mizrahi
Clin. Microbiol. Rev. 2006;19:558-570.
ABSTRACT
| FULL TEXT
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations
Cohen et al.
Proc. Natl. Acad. Sci. USA 2006;103:7042-7047.
ABSTRACT
| FULL TEXT
Update in tuberculosis 2005.
Yew and Leung
Am. J. Respir. Crit. Care Med. 2006;173:491-498.
FULL TEXT
Cost effectiveness analysis of strategies for tuberculosis control in developing countries
Baltussen et al.
BMJ 2005;331:1364.
ABSTRACT
| FULL TEXT
Multidrug-Resistant Tuberculosis in Hmong Refugees Resettling From Thailand Into the United States, 2004-2005
JAMA 2005;294:1753-1755.
FULL TEXT
Experts take on tuberculosis
Traynor
Am J Health Syst Pharm 2005;62:1431-1434.
FULL TEXT
Tuberculosis, Vulnerability, and Access to Quality Care
Hopewell and Pai
JAMA 2005;293:2790-2793.
FULL TEXT
Tuberculosis--A Global Problem Requiring a Global Solution
DeAngelis and Flanagin
JAMA 2005;293:2793-2794.
FULL TEXT
|
